Pathological gambling in Parkinson's disease—a review of the literature
Identifieur interne : 001330 ( Istex/Corpus ); précédent : 001329; suivant : 001331Pathological gambling in Parkinson's disease—a review of the literature
Auteurs : Atbin Djamshidian ; Francisco Cardoso ; Donald Grosset ; Henrietta Bowden-Jones ; Andrew J. LeesSource :
- Movement Disorders [ 0885-3185 ] ; 2011-09.
English descriptors
- KwdEn :
Abstract
The prevalence of pathological gambling is 3.4% to 6% in treated Parkinson's disease, which is higher than the background population rate. In this review we discuss current evidence to indicate that dopamine agonists are much more likely to trigger this behavior than either L‐dopa or selective monoamine oxidase B inhibitor monotherapy. New insights from recent behavioral and functional imaging studies and possible treatment approaches are also covered. A PubMed literature search using the terms “gambling” and “Parkinson's disease,” “impulse control disorder,” “impulsive compulsive behaviour,” “dopamine agonist,” of individual dopamine agonists, and of ongoing drug trials, using http://www.clinicaltrials.gov, was carried out for the period up to January 2011. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23821
Links to Exploration step
ISTEX:F71B531DEBB4BCCAC03F53B87E258C16E7E6C0A8Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pathological gambling in Parkinson's disease—a review of the literature</title><author><name sortKey="Djamshidian, Atbin" sort="Djamshidian, Atbin" uniqKey="Djamshidian A" first="Atbin" last="Djamshidian">Atbin Djamshidian</name><affiliation><mods:affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute for Neurological Studies, University of London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Cardoso, Francisco" sort="Cardoso, Francisco" uniqKey="Cardoso F" first="Francisco" last="Cardoso">Francisco Cardoso</name><affiliation><mods:affiliation>Movement Disorders Group, Neurology Service, Department of Internal Medicine, Federal University of Minas Gerais, Minas Gerais, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Grosset, Donald" sort="Grosset, Donald" uniqKey="Grosset D" first="Donald" last="Grosset">Donald Grosset</name><affiliation><mods:affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Bowden Ones, Henrietta" sort="Bowden Ones, Henrietta" uniqKey="Bowden Ones H" first="Henrietta" last="Bowden-Jones">Henrietta Bowden-Jones</name><affiliation><mods:affiliation>CNWL National Problem Gambling Clinic, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>Imperial College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name><affiliation><mods:affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute for Neurological Studies, University of London, London, United Kingdom</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F71B531DEBB4BCCAC03F53B87E258C16E7E6C0A8</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23821</idno><idno type="url">https://api.istex.fr/document/F71B531DEBB4BCCAC03F53B87E258C16E7E6C0A8/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001330</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pathological gambling in Parkinson's disease—a review of the literature</title><author><name sortKey="Djamshidian, Atbin" sort="Djamshidian, Atbin" uniqKey="Djamshidian A" first="Atbin" last="Djamshidian">Atbin Djamshidian</name><affiliation><mods:affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute for Neurological Studies, University of London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Cardoso, Francisco" sort="Cardoso, Francisco" uniqKey="Cardoso F" first="Francisco" last="Cardoso">Francisco Cardoso</name><affiliation><mods:affiliation>Movement Disorders Group, Neurology Service, Department of Internal Medicine, Federal University of Minas Gerais, Minas Gerais, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Grosset, Donald" sort="Grosset, Donald" uniqKey="Grosset D" first="Donald" last="Grosset">Donald Grosset</name><affiliation><mods:affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Bowden Ones, Henrietta" sort="Bowden Ones, Henrietta" uniqKey="Bowden Ones H" first="Henrietta" last="Bowden-Jones">Henrietta Bowden-Jones</name><affiliation><mods:affiliation>CNWL National Problem Gambling Clinic, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>Imperial College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name><affiliation><mods:affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute for Neurological Studies, University of London, London, United Kingdom</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-09">2011-09</date><biblScope unit="vol">26</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1976">1976</biblScope><biblScope unit="page" to="1984">1984</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">F71B531DEBB4BCCAC03F53B87E258C16E7E6C0A8</idno><idno type="DOI">10.1002/mds.23821</idno><idno type="ArticleID">MDS23821</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>adverse effects</term><term>compulsions</term><term>dopamine agonists</term><term>impulse control</term><term>pathological gambling</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The prevalence of pathological gambling is 3.4% to 6% in treated Parkinson's disease, which is higher than the background population rate. In this review we discuss current evidence to indicate that dopamine agonists are much more likely to trigger this behavior than either L‐dopa or selective monoamine oxidase B inhibitor monotherapy. New insights from recent behavioral and functional imaging studies and possible treatment approaches are also covered. A PubMed literature search using the terms “gambling” and “Parkinson's disease,” “impulse control disorder,” “impulsive compulsive behaviour,” “dopamine agonist,” of individual dopamine agonists, and of ongoing drug trials, using http://www.clinicaltrials.gov, was carried out for the period up to January 2011. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Atbin Djamshidian MD</name><affiliations><json:string>Department of Molecular Neuroscience and Reta Lila Weston Institute for Neurological Studies, University of London, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Francisco Cardoso MD, PhD</name><affiliations><json:string>Movement Disorders Group, Neurology Service, Department of Internal Medicine, Federal University of Minas Gerais, Minas Gerais, Brazil</json:string></affiliations></json:item><json:item><name>Donald Grosset MD, FRCP</name><affiliations><json:string>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</json:string></affiliations></json:item><json:item><name>Henrietta Bowden‐Jones MD</name><affiliations><json:string>CNWL National Problem Gambling Clinic, London, United Kingdom</json:string><json:string>Imperial College London, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Andrew J. Lees MD, FRCP</name><affiliations><json:string>Department of Molecular Neuroscience and Reta Lila Weston Institute for Neurological Studies, University of London, London, United Kingdom</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pathological gambling</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine agonists</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>impulse control</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>adverse effects</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>compulsions</value></json:item></subject><language><json:string>eng</json:string></language><abstract>The prevalence of pathological gambling is 3.4% to 6% in treated Parkinson's disease, which is higher than the background population rate. In this review we discuss current evidence to indicate that dopamine agonists are much more likely to trigger this behavior than either L‐dopa or selective monoamine oxidase B inhibitor monotherapy. New insights from recent behavioral and functional imaging studies and possible treatment approaches are also covered. A PubMed literature search using the terms “gambling” and “Parkinson's disease,” “impulse control disorder,” “impulsive compulsive behaviour,” “dopamine agonist,” of individual dopamine agonists, and of ongoing drug trials, using http://www.clinicaltrials.gov, was carried out for the period up to January 2011. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>6.344</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>801</abstractCharCount><pdfWordCount>6322</pdfWordCount><pdfCharCount>41769</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>112</abstractWordCount></qualityIndicators><title>Pathological gambling in Parkinson's disease—a review of the literature</title><genre><json:string>Serial article</json:string></genre><host><volume>26</volume><pages><total>9</total><last>1984</last><first>1976</first></pages><issn><json:string>0885-3185</json:string></issn><issue>11</issue><subject><json:item><value>Reviews</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23821</json:string></doi><id>F71B531DEBB4BCCAC03F53B87E258C16E7E6C0A8</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/F71B531DEBB4BCCAC03F53B87E258C16E7E6C0A8/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/F71B531DEBB4BCCAC03F53B87E258C16E7E6C0A8/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/F71B531DEBB4BCCAC03F53B87E258C16E7E6C0A8/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Pathological gambling in Parkinson's disease—a review of the literature</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Pathological gambling in Parkinson's disease—a review of the literature</title><author><persName><forename type="first">Atbin</forename><surname>Djamshidian</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute for Neurological Studies, University of London, London, United Kingdom</affiliation></author><author><persName><forename type="first">Francisco</forename><surname>Cardoso</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Movement Disorders Group, Neurology Service, Department of Internal Medicine, Federal University of Minas Gerais, Minas Gerais, Brazil</affiliation></author><author><persName><forename type="first">Donald</forename><surname>Grosset</surname><roleName type="degree">MD, FRCP</roleName></persName><affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</affiliation></author><author><persName><forename type="first">Henrietta</forename><surname>Bowden‐Jones</surname><roleName type="degree">MD</roleName></persName><affiliation>CNWL National Problem Gambling Clinic, London, United Kingdom</affiliation><affiliation>Imperial College London, London, United Kingdom</affiliation></author><author><persName><forename type="first">Andrew J.</forename><surname>Lees</surname><roleName type="degree">MD, FRCP</roleName></persName><note type="correspondence"><p>Correspondence: Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, 1 Wakefield St., London, WC1N 1PJ, UK</p></note><affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute for Neurological Studies, University of London, London, United Kingdom</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-09"></date><biblScope unit="vol">26</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1976">1976</biblScope><biblScope unit="page" to="1984">1984</biblScope></imprint></monogr><idno type="istex">F71B531DEBB4BCCAC03F53B87E258C16E7E6C0A8</idno><idno type="DOI">10.1002/mds.23821</idno><idno type="ArticleID">MDS23821</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The prevalence of pathological gambling is 3.4% to 6% in treated Parkinson's disease, which is higher than the background population rate. In this review we discuss current evidence to indicate that dopamine agonists are much more likely to trigger this behavior than either L‐dopa or selective monoamine oxidase B inhibitor monotherapy. New insights from recent behavioral and functional imaging studies and possible treatment approaches are also covered. A PubMed literature search using the terms “gambling” and “Parkinson's disease,” “impulse control disorder,” “impulsive compulsive behaviour,” “dopamine agonist,” of individual dopamine agonists, and of ongoing drug trials, using http://www.clinicaltrials.gov, was carried out for the period up to January 2011. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>pathological gambling</term></item><item><term>dopamine agonists</term></item><item><term>impulse control</term></item><item><term>adverse effects</term></item><item><term>compulsions</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Reviews</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-02-22">Received</change><change when="2011-05-12">Registration</change><change when="2011-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/F71B531DEBB4BCCAC03F53B87E258C16E7E6C0A8/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="110"><doi origin="wiley" registered="yes">10.1002/mds.v26.11</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">11</numbering></numberingGroup><coverDate startDate="2011-09">September 2011</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="50" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23821</doi><idGroup><id type="unit" value="MDS23821"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="articleCategory">Reviews</title><title type="tocHeading1">Reviews</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2011-02-22"></event><event type="manuscriptRevised" date="2011-05-08"></event><event type="manuscriptAccepted" date="2011-05-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.10 mode:FullText" date="2011-09-19"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-06-09"></event><event type="firstOnline" date="2011-06-09"></event><event type="publishedOnlineFinalForm" date="2011-09-19"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1976</numbering><numbering type="pageLast">1984</numbering></numberingGroup><correspondenceTo>Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, 1 Wakefield St., London, WC1N 1PJ, UK</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23821.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="103"></count><count type="wordTotal" number="7845"></count></countGroup><titleGroup><title type="main" xml:lang="en">Pathological gambling in Parkinson's disease—a review of the literature<link href="#fn1"></link><link href="#fn2"></link></title><title type="short" xml:lang="en">Pathological Gambling in PD: Review</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Atbin</givenNames><familyName>Djamshidian</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Francisco</givenNames><familyName>Cardoso</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Donald</givenNames><familyName>Grosset</familyName><degrees>MD, FRCP</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4 #af5"><personName><givenNames>Henrietta</givenNames><familyName>Bowden‐Jones</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Andrew J.</givenNames><familyName>Lees</familyName><degrees>MD, FRCP</degrees></personName><contactDetails><email>alees@ion.ucl.ac.uk</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute for Neurological Studies, University of London, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="BR" type="organization"><unparsedAffiliation>Movement Disorders Group, Neurology Service, Department of Internal Medicine, Federal University of Minas Gerais, Minas Gerais, Brazil</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="GB" type="organization"><unparsedAffiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="GB" type="organization"><unparsedAffiliation>CNWL National Problem Gambling Clinic, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="GB" type="organization"><unparsedAffiliation>Imperial College London, London, United Kingdom</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">pathological gambling</keyword><keyword xml:id="kwd3">dopamine agonists</keyword><keyword xml:id="kwd4">impulse control</keyword><keyword xml:id="kwd5">adverse effects</keyword><keyword xml:id="kwd6">compulsions</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The prevalence of pathological gambling is 3.4% to 6% in treated Parkinson's disease, which is higher than the background population rate. In this review we discuss current evidence to indicate that dopamine agonists are much more likely to trigger this behavior than either <sc>L</sc>‐dopa or selective monoamine oxidase B inhibitor monotherapy. New insights from recent behavioral and functional imaging studies and possible treatment approaches are also covered. A PubMed literature search using the terms “gambling” and “Parkinson's disease,” “impulse control disorder,” “impulsive compulsive behaviour,” “dopamine agonist,” of individual dopamine agonists, and of ongoing drug trials, using <url href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</url>, was carried out for the period up to January 2011. © 2011 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p><b>Relevant conflicts of interest/financial disclosures:</b> Nothing to report.</p></note><note xml:id="fn2"><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Pathological gambling in Parkinson's disease—a review of the literature</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Pathological Gambling in PD: Review</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Pathological gambling in Parkinson's disease—a review of the literature</title></titleInfo><name type="personal"><namePart type="given">Atbin</namePart><namePart type="family">Djamshidian</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute for Neurological Studies, University of London, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Francisco</namePart><namePart type="family">Cardoso</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Movement Disorders Group, Neurology Service, Department of Internal Medicine, Federal University of Minas Gerais, Minas Gerais, Brazil</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Donald</namePart><namePart type="family">Grosset</namePart><namePart type="termsOfAddress">MD, FRCP</namePart><affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Henrietta</namePart><namePart type="family">Bowden‐Jones</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>CNWL National Problem Gambling Clinic, London, United Kingdom</affiliation><affiliation>Imperial College London, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andrew J.</namePart><namePart type="family">Lees</namePart><namePart type="termsOfAddress">MD, FRCP</namePart><affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute for Neurological Studies, University of London, London, United Kingdom</affiliation><description>Correspondence: Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, 1 Wakefield St., London, WC1N 1PJ, UK</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">reviewArticle</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-09</dateIssued><dateCaptured encoding="w3cdtf">2011-02-22</dateCaptured><dateValid encoding="w3cdtf">2011-05-12</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="references">103</extent><extent unit="words">7845</extent></physicalDescription><abstract lang="en">The prevalence of pathological gambling is 3.4% to 6% in treated Parkinson's disease, which is higher than the background population rate. In this review we discuss current evidence to indicate that dopamine agonists are much more likely to trigger this behavior than either L‐dopa or selective monoamine oxidase B inhibitor monotherapy. New insights from recent behavioral and functional imaging studies and possible treatment approaches are also covered. A PubMed literature search using the terms “gambling” and “Parkinson's disease,” “impulse control disorder,” “impulsive compulsive behaviour,” “dopamine agonist,” of individual dopamine agonists, and of ongoing drug trials, using http://www.clinicaltrials.gov, was carried out for the period up to January 2011. © 2011 Movement Disorder Society</abstract><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>pathological gambling</topic><topic>dopamine agonists</topic><topic>impulse control</topic><topic>adverse effects</topic><topic>compulsions</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Reviews</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>11</number></detail><extent unit="pages"><start>1976</start><end>1984</end><total>9</total></extent></part></relatedItem><identifier type="istex">F71B531DEBB4BCCAC03F53B87E258C16E7E6C0A8</identifier><identifier type="DOI">10.1002/mds.23821</identifier><identifier type="ArticleID">MDS23821</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001330 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001330 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:F71B531DEBB4BCCAC03F53B87E258C16E7E6C0A8
|texte= Pathological gambling in Parkinson's disease—a review of the literature
}}
| This area was generated with Dilib version V0.6.23. |  |